• Review • Previous Articles     Next Articles

Correlation between 11β-hydroxysteroid dehydrogenase and metabolic syndrome

RUAN Li-li1,2, ZOU Chao-chun1   

  1. 1.Department of Endocrinology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; 2.Department of Pediatrics, the Second People's Hospital, Hangzhou 310015, China
  • Online:2014-06-28 Published:2014-06-30
  • Supported by:

    Zhejiang province Science and Technology Innovation Team Focused on Independent Projects,2010R50045


Metabolic syndrome (MetS) is a pathological condition of disorders of several metabolic components and a risk factor of causing cardiovascular diseases and diabetes. Dysregulation of glucocorticoid is an important feature of MetS. 11β-hydroxysteroid dehydrogenase (11β-HSD) of the body mainly converts the active glucocorticoid to its inactive precursor and regulates the concentration of local glucocorticoid. 11β-HSD involves pathophysiologic processes of MetS such as insulin resistance, obesity, type 2 diabetes, and hypertension. The application of 11β-HSD1 inhibitors may provide new methods for treating MetS.

Key words: metabolic syndrome, 11β-hydroxysteroid dehydrogenases, cardiovascular diseases, diabete, 11β-hydroxysteroid dehydrogenases inhibitors